All In Biotech

Drug Trial Radar · NCT00866970

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of ALD518 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia

Last checked: Nov 20, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Sep 2008

Primary completion

Aug 2009

Study completion Dec 2009

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Mar 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to asses the safety and efficacy of ALD518 in patients with Non-Small Cell Lung Cancer-Related Fatigue and cachexia (weight-loss).

Conditions

  • NSCLC
  • Fatigue
  • Cachexia

Interventions

  • ALD518Biological

    ALD518 80 mg on Day 1, Week 8 and Week 16

  • ALD518Biological

    ALD518 160 mg IV on Day 1, Week 8 and Week 16

  • ALD518Biological

    ALD518 360 mg IV on Day 1, Week 8, and Week 16

  • Infusion of 0.9% Saline without ALD518Biological

    Infusion of 0.9% Saline without addition of ALD518

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Safety parameters.Time frame: 20 weeks

Locations

43 sites in 9 countries. Site status is shown where the registry gives one.

  • Rivercity Hospital Research Centre

    Auchenflower, Queensland, Australia

  • Australian Clinical Research Organisation

    Kippa-Ring, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Palliative Care Launceston General Hospital

    Launceston, Tasmania, Australia

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Atlantic Health Sciences Corporation

    Saint John, New Brunswick, Canada

  • McGill University, Department of Oncology

    Montreal, Quebec, Canada

  • A. Gvamichava National Cancer Centre

    Tbilisi, Georgia

  • Union Cancer Prevention Centre

    Tbilisi, Georgia

  • Medulla Chemotherapy and Immunotherapy Clinic

    Tbilisi, Georgia

  • Kidwai Memorial Institute of Oncology

    Bangalore, India

  • Kailash Cancer Hospital and Research Centre

    Gujarat, India

  • IndoAmerican Cancer Institute & Research Center

    Hyderabad, India

  • SEAROC Cancer Centre

    Jaipur, India

  • Orchid Nursing Home

    Kolkata, India

  • Tata Memorial Hospital

    Mumbai, India

  • Shatabdi Hospital

    Mumbai, India

  • Mahavir Cancer Sansthan

    Patna, India

  • Jehangir Clinical Development Centre Pvt. Ltd.

    Pune, India

  • Indira Gandhi Institute of Medical Sciences

    Patna, Bihar, India

  • Dr. Kamakshi Memorial Hospital

    Pallikaranai, Chennai, India

  • GKNM Hospital

    Pappanaickenpalayam, Coimbatore, India

  • Curie Manavata Cancer Centre

    Nashik, Maharashtra, India

  • P3 Research LTD

    Tauranga, New Zealand

  • Oddzial Chorob Pluc i Leczenia Raka Pluc

    Bydgoszcz, Poland

  • Oddzial Chemioterapii Szpital Morski

    Gdynia, Poland

  • II Oddzia Chorob Pluc z Pododdzialem Chemioterapii

    Krakow, Poland

  • Oddzial II Chemioterapii Specjalistyczny Szpital

    Szczecin, Poland

  • Professor Dr. Al Trestioreanu Institute

    Bucharest, Romania

  • Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy

    Cluj-Napoca, Romania

  • Oradea Clinical County Hospital Medical Oncology Department

    Oradea, Romania

  • County Hospital Sibiu Medical Oncology Department

    Sibiu, Romania

  • City Clinical Hospital No. 1

    Novosibirsk, Russia

  • Saint-Petersburg State Medical University, I.P. Pavlov

    Saint Petersburg, Russia

  • St. Petersburg City Oncology Dispensary

    Saint Petersburg, Russia

  • Yaroslavl Regional clinical Oncology Hospital

    Yaroslavl, Russia

  • Republic Oncology Dispensary

    Ufa, Bashkortostan Republic, Russia

  • Territorial Clinical Oncology Dispensary

    Krasnodar, Krasnodar Territory, Russia

  • Stavropol Territorial Clinical

    Pyatigorsk, Stavropol Territory, Russia

  • Institute of Lung Diseases and TB

    Belgrade, Serbia

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.